Dec 7, 2017 Vedanta Biosciences Announces Initiation of Phase 1a/1b Trial for New Drug Class of Rationally-Defined Bacterial Consortia Derived from the Human Microbiome
Nov 29, 2017 Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy
Nov 2, 2017 CARB-X awards up to $5.4M to Vedanta Biosciences to accelerate the development of a novel human microbiome-derived treatment for deadly C. difficile bacterial infections
Nov 1, 2017 Vedanta Biosciences to Advance Cancer Immunotherapy Candidates Based on Microbiome-Derived Live Biotherapeutics that Induce CD8+ T Cells
May 30, 2017 Vedanta Biosciences Granted U.S. Patent Broadly Covering Methods of Treatment with Therapeutics Based on Bacterial Spore Fractions of Microbiota Obtained From Human Donors
May 16, 2017 Vedanta Biosciences Granted Three U.S. Patents Broadly Covering Pharmaceutical Compositions and Methods of Use for Therapeutics Based on Immune-Modulating Bacterial Consortia
Feb 16, 2017 Vedanta Biosciences Announces Clinical Translational Medicine Collaborations with Stanford University School of Medicine and Leiden University Medical Center
Oct 19, 2016 Vedanta Biosciences Granted First European Patent Broadly Covering Pharmaceutical Compositions for Microbiome Therapeutics Based on Bacterial Consortia
Sep 6, 2016 Vedanta Biosciences Granted Third U.S. Patent Covering Methods of Treating Infectious and Allergic Diseases with Bacterial Consortia
Aug 23, 2016 Vedanta Biosciences Granted Second U.S. Patent Covering Methods of Treating Autoimmune Disease with Therapeutics Based on Bacterial Consortia
